Companies rush to produce pot products, without the cannabis plant itself

CannTrust Holdings Inc.'s chief executive Peter Aceto said the Vaughan, Ont.-based licensed producer has a short list of biosynthesis companies that it is in active conversations with, which could result in either a partnership or acquisition.

Synthetic cannabinoid production has the potential to disrupt the cannabis industry supply chain, he added in a recent note. Cronos' chief executive Michael Gorenstein said during a recent conference call that this partnership is key to its strategy of focusing on developing branded products and intellectual property, rather than the capital-intensive process of cultivation and production. He added that Cronos and Ginkgo will focus on synthetic production of THC, the compound which produces a high, and CBD, the non-impairing compound believed to have anti-inflammatory properties.

It's similar to brewing beer, where water, yeast and malted grain are combined and fermented to produce an alcoholic beverage. However, the yeast is instead genetically engineered to produce the necessary enzymes to yield cannabinoids instead.

No thanks.

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Why business is booming for cannabis extraction companies, despite the supply shortagesAlthough licensed producers are getting into extraction, observers predict it won’t be enough to meet future demand for cannabis in oil-form MediPharmLabs Anyone interested in investing in this can follow me for news.
ソース: nationalpost - 🏆 10. / 80 続きを読む »

Maple Leaf Foods expands plant-based protein business with new Indiana plantIt will also invest approximately US$26-million to keep pace with growth in demand at its existing facilities globebusiness Where's the meat?
ソース: globeandmail - 🏆 5. / 92 続きを読む »